DiNAQOR AG, an innovative health technology group advancing promising early-stage drug development, announced strategic leadership appointments that strengthen its position as a life science company builder focused on creating, scaling, and partnering next-generation biotechnology ventures. The appointments signal the company's commitment to translating scientific innovation into impactful biotechnology companies through advanced, human-relevant nonclinical testing methods.
Dr. Christian Thirion has been appointed Chief Executive Officer and Delegate of the Board of Directors of DiNATEQ AG, the recently established DiNAQOR spin-out focused on clinical translation of the closed-loop loco-regional perfusion (LRP) delivery platform. Additionally, Dr. Thirion assumes the newly created role of Chief Strategy and Business Development Officer of DiNAQOR AG, where he will lead group-wide corporate strategy, strategic partnerships, and M&A activities. Dr. Thirion brings more than two decades of entrepreneurial and executive leadership experience, having founded Sirion Biotech and built it into a global market leader in viral vector engineering and AAV-based gene delivery before its acquisition by PerkinElmer in a landmark transaction.
Johannes Holzmeister, Founder of the DiNAQOR Group and Chairman and CEO of DINAQOR AG, stated that Dr. Thirion's combination of visionary entrepreneurship, disciplined operation, and partnership experience significantly strengthens the company's ability to build companies, execute partnerships, and translate breakthrough technologies into clinical and commercial success. Dr. Thirion emphasized that DiNAQOR has built an exceptional ecosystem for turning scientific innovation into impactful biotechnology companies, noting that the closed-loop perfusion platform represents a truly differentiated delivery technology with potential to unlock multiple therapeutic modalities across organs.
In parallel, DiNAQOR Group AG announced the appointment of Dr. Josef El Andari as Chief Scientific Officer of DiNAQOR AG. Dr. El Andari has been with DiNAQOR for more than four years and played a central role in advancing the company's scientific platforms, including development of the closed-loop perfusion technology from early concept through publication in leading peer-reviewed journals. His expertise spans genomic medicine, translational research, and advanced viral vector technologies, with particular focus on AAV design and bioengineering. Dr. El Andari expressed honor in taking on the Chief Scientific Officer role and commitment to translating rigorous science into therapies with real clinical impact that are scalable, clinically relevant, and aligned with the highest scientific standards.
These leadership appointments occur as DiNAQOR continues to demonstrate its company-building and value-creation capabilities through strategic transactions, including the recent M&A of DiNAMIQS, a specialized adeno-associated virus (AAV) manufacturing and development company. The company operates as a life science company builder, creating and scaling focused biotechnology companies around differentiated technology platforms while integrating proprietary delivery platforms, vector innovation, and translational expertise to enable safer, more effective therapies for organ-specific diseases. For more information visit https://www.dinaqor.com.
